WEP Clinical
The Lead Mobile Research Nurse at WEP Clinical provides decentralized clinical trial nursing services to participants in their homes while offering regional support and oversight to per-diem research nurses. The role focuses on delivering high-quality patient care within clinical research protocols and regulatory standards. It is a home-based position with extensive regional travel, contributing directly to advancing clinical research and improving patient access to investigational treatments. The nurse also plays a key role in training, mentoring, and supporting other mobile research nurses.
Headquarters
London, England, United Kingdom
Company Size
51-200 employees
Founded
2008
WEP Clinical is a full-service, "Complete CRO" built for biotech sponsors, offering bespoke services across the full lifecycle of drug development. They deliver clinical trial management (Phase I–IV) and complementary Treatment Access, Market Access and Commercialization solutions to help sponsors advance medicines and reach patients worldwide. With a proven track record supporting 60+ clinical programs globally, WEP focuses on tailored strategies to accelerate development, access and launch.
WEP Clinical Acquires Netherlands-Based CRO Siron Clinical, Expanding Global Phase I–IV Trial Delivery Capabilities
1 month ago
WEP Clinical has partnered with Theratechnologies to launch a Named Patient Program for EGRIFTA SV®
Aug 8, 2023
Continuing Rare Disease Treatment With A Compassionate Use Program (CUP)
Oct 2, 2024
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for WEP Clinical .
WEP Clinical didn’t post a salary, so this is our estimate from similar listings.
WEP Clinical has partnered with TaiMed Biologics to launch a Trogarzo named patient program
Mar 27, 2023